Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors

Genome Biology

Volumn 14, Issue 4, 2013, Pages

  Casado, Pedro ^a   Alcolea, Maria P ^a   Iorio, Francesco ^b,c   Rodríguez Prados, Juan Carlos ^a   Vanhaesebroeck, Bart ^a   Saez Rodriguez, Julio ^b   Joel, Simon ^a   Cutillas, Pedro R ^a,d  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^c WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; JANUS KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN KINASE INHIBITOR; PROTEOME;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER CLASSIFICATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; LYMPHOMA; MASS SPECTROMETRY; MULTIPLE MYELOMA; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; PROTEOMICS; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; PHOSPHORYLATION; PROTEIN PROCESSING; TUMOR CELL LINE;

CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA; MULTIPLE MYELOMA; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOME;

EID: 84876795631     PISSN: None     EISSN: 1474760X     Source Type: Journal    
DOI: 10.1186/gb-2013-14-4-r37     Document Type: Article

References (58)

1. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol 2000, 13:193-207. 10.1038/modpathol.3880035, 10697278.
2. Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD, Sallan SE, Lander ES, Golub TR, Korsmeyer SJ. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002, 30:41-47. 10.1038/ng765, 11731795.
3. Levene AP, Morgan GJ, Davies FE. The use of genetic microarray analysis to classify and predict prognosis in haematological malignancies. Clin Lab Haematol 2003, 25:209-220. 10.1046/j.1365-2257.2003.00532.x, 12890159.
4. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999, 286:531-537. 10.1126/science.286.5439.531, 10521349.
5. Pascal LE, True LD, Campbell DS, Deutsch EW, Risk M, Coleman IM, Eichner LJ, Nelson PS, Liu AY. Correlation of mRNA and protein levels: cell type-specific gene expression of cluster designation antigens in the prostate. BMC Genomics 2008, 9:246. 10.1186/1471-2164-9-246, 2413246, 18501003.
6. Greenbaum D, Colangelo C, Williams K, Gerstein M. Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biol 2003, 4:117. 10.1186/gb-2003-4-9-117, 193646, 12952525.
7. Cascante M, Boros LG, Comin-Anduix B, de Atauri P, Centelles JJ, Lee PW. Metabolic control analysis in drug discovery and disease. NaBiotechnol 2002, 20:243-249.
8. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674. 10.1016/j.cell.2011.02.013, 21376230.
9. O'Hare T, Zabriskie MS, Eide CA, Agarwal A, Adrian LT, You H, Corbin AS, Yang F, Press RD, Rivera VM, Toplin J, Wong S, Deininger MW, Druker BJ. The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Blood 2011, 118:5250-5254. 10.1182/blood-2011-05-349191, 3217407, 21908430.
10. Boulos N, Mulder HL, Calabrese CR, Morrison JB, Rehg JE, Relling MV, Sherr CJ, Williams RT. Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2011, 117:3585-3595. 10.1182/blood-2010-08-301267, 3072880, 21263154.
11. Kelloff GJ, Sigman CC. Cancer biomarkers: selecting the right drug for the right patient. NatRev Drug Discov 2012, 11:201-214.
12. Druker BJ. Perspectives on the development of imatinib and the future of cancer research. NatMed 2009, 15:1149-1152.
13. Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, Chandarlapaty S, Markman B, Rodriguez O, Guzman M, Rodriguez S, Gili M, Russillo M, Parra JL, Singh S, Arribas J, Rosen N, Baselga J. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 2011, 30:2547-2557. 10.1038/onc.2010.626, 3107390,3107390, 21278786.
14. Liu P, Cheng H, Santiago S, Raeder M, Zhang F, Isabella A, Yang J, Semaan DJ, Chen C, Fox EA, Gray NS, Monahan J, Schlegel R, Beroukhim R, Mills GB, Zhao JJ. Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. NatMed 2011, 17:1116-1120.
15. Manning G, Plowman GD, Hunter T, Sudarsanam S. Evolution of protein kinase signaling from yeast to man. Trends Biochem Sci 2002, 27:514-520. 10.1016/S0968-0004(02)02179-5, 12368087.
16. Casado P, Cutillas PR. A self-validating quantitative mass spectrometry method for assessing the accuracy of high-content phosphoproteomic experiments. MolCellProteomics 2011, 10:M110 003079.
17. Linding R, Jensen LJ, Ostheimer GJ, van Vugt MA, Jorgensen C, Miron IM, Diella F, Colwill K, Taylor L, Elder K, Metalnikov P, Nguyen V, Pasculescu A, Jin J, Park JG, Samson LD, Woodgett JR, Russell RB, Bork P, Yaffe MB, Pawson T. Systematic discovery of in vivo phosphorylation networks. Cell 2007, 129:1415-1426. 10.1016/j.cell.2007.05.052, 2692296, 17570479.
18. Choudhary C, Mann M. Decoding signalling networks by mass spectrometry-based proteomics. NatRev MolCell Biol 2010, 11:427-439.
19. Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, Lim D, Peterson TR, Choi Y, Gray NS, Yaffe MB, Marto JA, Sabatini DM. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 2011, 332:1317-1322. 10.1126/science.1199498, 3177140, 21659604.
20. Gioia R, Leroy C, Drullion C, Lagarde V, Etienne G, Dulucq S, Lippert E, Roche S, Mahon FX, Pasquet JM. Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells. Blood 2011, 118:2211-2221. 10.1182/blood-2010-10-313692, 21730355.
21. Rubbi L, Titz B, Brown L, Galvan E, Komisopoulou E, Chen SS, Low T, Tahmasian M, Skaggs B, Muschen M, Pellegrini M, Graeber TG. Global phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signaling. Sci Signal 2011, 4:ra18. 10.1126/scisignal.2001314, 21447799.
22. Choudhary C, Olsen JV, Brandts C, Cox J, Reddy PN, Bohmer FD, Gerke V, Schmidt-Arras DE, Berdel WE, Muller-Tidow C, Mann M, Serve H. Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell 2009, 36:326-339. 10.1016/j.molcel.2009.09.019, 19854140.
23. Klammer M, Kaminski M, Zedler A, Oppermann F, Blencke S, Marx S, Muller S, Tebbe A, Godl K, Schaab C. Phosphosignature predicts dasatinib response in non-small cell lung cancer. MolCellProteomics 2012, 11:651-668.
24. Alcolea MP, Kleiner O, Cutillas PR. Increased confidence in large-scale phosphoproteomics data by complementary mass spectrometric techniques and matching of phosphopeptide data sets. J Proteome Res 2009, 8:3808-3815. 10.1021/pr800955n, 19537829.
25. Neilson KA, Ali NA, Muralidharan S, Mirzaei M, Mariani M, Assadourian G, Lee A, van Sluyter SC, Haynes PA. Less label, more free: approaches in label-free quantitative mass spectrometry. Proteomics 2011, 11:535-553. 10.1002/pmic.201000553, 21243637.
26. Schmidt A, Beck M, Malmstrom J, Lam H, Claassen M, Campbell D, Aebersold R. Absolute quantification of microbial proteomes at different states by directed mass spectrometry. MolSystBiol 2011, 7:510.
27. Geiger T, Wehner A, Schaab C, Cox J, Mann M. Comparative proteomic analysis of eleven common cell lines reveals ubiquitous but varying expression of most proteins. MolCellProteomics 2012, 11:M111 014050.
28. Alcolea MP, Casado P, Rodriguez-Prados JC, Vanhaesebroeck B, Cutillas PR. Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance. MolCellProteomics 2012, 11:453-466.
29. Schilling B, Rardin MJ, MacLean BX, Zawadzka AM, Frewen BE, Cusack MP, Sorensen DJ, Bereman MS, Jing E, Wu CC, Verdin E, Kahn CR, Maccoss MJ, Gibson BW. Platform-independent and label-free quantitation of proteomic data using MS1 extracted ion chromatograms in skyline: application to protein acetylation and phosphorylation. MolCellProteomics 2012, 11:202-214.
30. Stulemeijer IJ, Joosten MH, Jensen ON. Quantitative phosphoproteomics of tomato mounting a hypersensitive response reveals a swift suppression of photosynthetic activity and a differential role for hsp90 isoforms. J Proteome Res 2009, 8:1168-1182. 10.1021/pr800619h, 19178300.
31. Bodenmiller B, Wanka S, Kraft C, Urban J, Campbell D, Pedrioli PG, Gerrits B, Picotti P, Lam H, Vitek O, Brusniak MY, Roschitzki B, Zhang C, Shokat KM, Schlapbach R, Colman-Lerner A, Nolan GP, Nesvizhskii AI, Peter M, Loewith R, von Mering C, Aebersold R. Phosphoproteomic analysis reveals interconnected system-wide responses to perturbations of kinases and phosphatases in yeast. Sci Signal 2010, 3:rs4. 10.1126/scisignal.2001182, 3072779, 21177495.
32. Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P, Mann M. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 2006, 127:635-648. 10.1016/j.cell.2006.09.026, 17081983.
33. Qureshi AH, Chaoji V, Maiguel D, Faridi MH, Barth CJ, Salem SM, Singhal M, Stoub D, Krastins B, Ogihara M, Zaki MJ, Gupta V. Proteomic and phospho-proteomic profile of human platelets in basal, resting state: insights into integrin signaling. PLoS One 2009, 4:e7627. 10.1371/journal.pone.0007627, 2762604, 19859549.
34. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000, 25:25-29. 10.1038/75556, 3037419, 10802651.
35. Huang da W, Sherman BT, Tan Q, Kir J, Liu D, Bryant D, Guo Y, Stephens R, Baseler MW, Lane HC, Lempicki RA. DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res 2007, 35:W169-175. 10.1093/nar/gkm415, 1933169, 17576678.
36. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. GeneDev 2002, 16:1472-1487.
37. Ramsden JJ. MARCKS: a case of molecular exaptation?. IntJ BiochemCell Biol 2000, 32:475-479.
38. Beretta L, Dubois MF, Sobel A, Bensaude O. Stathmin is a major substrate for mitogen-activated protein kinase during heat shock and chemical stress in HeLa cells. EurJBiochem 1995, 227:388-395.
39. Hayashi K, Pan Y, Shu H, Ohshima T, Kansy JW, White CL, Tamminga CA, Sobel A, Curmi PA, Mikoshiba K, Bibb JA. Phosphorylation of the tubulin-binding protein, stathmin, by Cdk5 and MAP kinases in the brain. JNeurochem 2006, 99:237-250.
40. Schwartz D, Gygi SP. An iterative statistical approach to the identification of protein phosphorylation motifs from large-scale data sets. NatBiotechnol 2005, 23:1391-1398.
41. Miller ML, Jensen LJ, Diella F, Jorgensen C, Tinti M, Li L, Hsiung M, Parker SA, Bordeaux J, Sicheritz-Ponten T, Olhovsky M, Pasculescu A, Alexander J, Knapp S, Blom N, Bork P, Li S, Cesareni G, Pawson T, Turk BE, Yaffe MB, Brunak S, Linding R. Linear motif atlas for phosphorylation-dependent signaling. Science Signaling 2008, 1:ra2. 10.1126/scisignal.1159433, 18765831.
42. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfield CD. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114:937-951. 10.1182/blood-2009-03-209262, 19357394.
43. Sawyers CL. The cancer biomarker problem. Nature 2008, 452:548-552. 10.1038/nature06913, 18385728.
44. Gonzalez-Angulo AM, Hennessy BT, Meric-Bernstam F, Sahin A, Liu W, Ju Z, Carey MS, Myhre S, Speers C, Deng L, Broaddus R, Lluch A, Aparicio S, Brown P, Pusztai L, Symmans WF, Alsner J, Overgaard J, Borresen-Dale AL, Hortobagyi GN, Coombes KR, Mills GB. Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. CliProteomics 2011, 8:11.
45. Lee JM, Kohn EC. Proteomics as a guiding tool for more effective personalized therapy. AnnOncol 2010, (Suppl 7):vii205-210.
46. Deeb SJ, D'Souza RC, Cox J, Schmidt-Supprian M, Mann M. Super-SILAC Allows Classification of Diffuse Large B-cell Lymphoma Subtypes by Their Protein Expression Profiles. MolCellProteomics 2012, 11:77-89.
47. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005, 4:988-1004. 10.1038/nrd1902, 16341064.
48. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26:3291-3310. 10.1038/sj.onc.1210422, 17496923.
49. Dan S, Okamura M, Seki M, Yamazaki K, Sugita H, Okui M, Mukai Y, Nishimura H, Asaka R, Nomura K, Ishikawa Y, Yamori T. Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations. Cancer Res 2010, 70:4982-4994. 10.1158/0008-5472.CAN-09-4172, 20530683.
50. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R. PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations. JClinOncol 2012, 10:777-782.
51. Piloto O, Wright M, Brown P, Kim KT, Levis M, Small D. Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. Blood 2007, 109:1643-1652. 10.1182/blood-2006-05-023804, 1794049, 17047150.
52. Balmanno K, Chell SD, Gillings AS, Hayat S, Cook SJ. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. Int J Cancer 2009, 125:2332-2341. 10.1002/ijc.24604, 19637312.
53. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 1999, 20:3551-3567. 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2, 10612281.
54. See http://expasy.org/sprot/.
55. Vizcaino JA, Cote RG, Csordas A, Dianes JA, Fabregat A, Foster JM, Griss J, Alpi E, Birim M, Contell J, O'Kelly G, Schoenegger A, Ovelleiro D, Pérez-Riverol Y, Reisinger F, Ríos D, Wang R, Hermjakob H. The PRoteomics IDEntifications (PRIDE) database and associated tools: status in 2013. Nucleic Acids Res 2013, 41:D1063-1069. 10.1093/nar/gks1262, 3531176, 23203882.
56. See http://proteomecentral.proteomexchange.org.
57. Savitski MM, Lemeer S, Boesche M, Lang M, Mathieson T, Bantscheff M, Kuster B. Confident phosphorylation site localization using the Mascot Delta Score. Mol Cell Proteomics 2010, 10:M110 003830. 3033680, 21057138.
58. Tibshirani R. The lasso method for variable selection in the Cox model. StatMed 1997, 16:385-395.